Financial Security Advisor’s Neurocrine Biosciences NBIX Stock Holding History

Financial Security Advisor’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$381K	Buy	+2,688	New	+$432K	0.06%	112

Other funds holding NBIX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Financial Security Advisor's NBIX Position: Q3 2026 in Review

Financial Security Advisor opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 2,688 shares worth $381K. The stake represents 0.06% of the portfolio and ranks #112 among its holdings.

630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Financial Security Advisor held 2,688 shares of Neurocrine Biosciences worth $381K as of Q3 2026.
Neurocrine Biosciences was a new Financial Security Advisor position in Q3 2026.
Neurocrine Biosciences made up 0.06% of Financial Security Advisor's portfolio in Q3 2026, its #112 holding.
630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Financial Security Advisor's 13F filing for Q3 2026, filed 3 Nov 2026.